

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Parkinson's disease (PD)	Serotonin receptor (5-HT1B receptor)	A study in rodents suggests that 5-HT1B receptor agonists might be useful for reducing L-DOPA side effects in PD patients. Chronic L-DOPA administration to mice and rats with lesions increased levels of the 5-HT1B receptor and its adaptor protein p11 in striatonigral neurons. In addition, wild-type mice with lesions treated with the 5-HT1B receptor agonist CP9423 showed reduced L-DOPA-induced behavioral side effects compared with p11 knockout mice with lesions. Next steps could include safety and toxicology studies of CP9423.	Patent and licensing status undisclosed	Zhang, X. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Feb. 6, 2008; doi:10.1073/pnas.0711839105 Contact: Per Svenningsson, Karolinska Institute, Stockholm, Sweden e-mail: per.svenningsson@ki.se Contact: Paul Greengard, The Rockefeller University, New York, N.Y. e-mail: greengard@rockefeller.edu